Dear Editor,
hrombotic thrombocytopenic purpura (TTP) is a rare disease of unknown etiology characterized by severe thrombocytopenia, microangiopathic hemolytic anemia, fever, renal, neurologic and rarely cardiac involvement [1] . All cases of microangiopathic hemolytic anemia with thrombocytopenia should be considered as TTP and the treatment must be initiated immediately until the contrary is proved [1, 2] .
A 48-year-old female patient with the history of diabetes mellitus and hypertension, immunosuppressive drugs user caused by vasculitis, was admitted to our clinic with vasculitis attack. Reference values are summarized in Table 1 . Twentyfour hour urine protein was detected as 8 g/day. Renal biopsy findings were consistent with thrombotic microangiopathy. Pulse steroid (1g/day) was administered for 3 days and then 1 mg/kg methylprednisolone was continued. Cyclophosphamide 500 mg/m 2 was applied because of persistent pancytopenia. Peripheral blood smear revealed blister cells, rare normoblasts and schistocytes. Direct Coombs test was negative. TTP was considered because the patient presented both microangiopathic hemolytic anemia with thrombocytopenia. Cyclophosphamide 500 mg/m 2 was administered again because of totally 37 times unsuccessful therapeutic apheresis therapy and other signs of systemic vasculitis. Rituximab 1000 mg was applied on the on the first and fifteenth days because the low platelets count, refractory microangiopathic hemolytic anemia. Pancytopenia had benefits ( Figure  1 ), proteinuria level decreased to 885 mg/day, the other systemic vasculitis signs (polyneuropathy, pretibial edema) were regressed and the patient was discharged in a healthy condition.
Plasma exchange procedure show a significant effect in treatment of TTP; all adult patients met the diagnostic criteria should be applied plasma exchange [3] [4] [5] . Plasma exchange may be effective in immunosuppressive treatment-resistant cases. According to the McDonald et al.'s study [5] in London University, rituximab therapy may be more effective in cases of high active ADAMST13 IgG antibodies study then low active ADAMST13 antibodies. It is clear that effective doses, location and maintenance of rituximab therapy should be studied in terms of TTP. All cases of microangiopathic hemolytic anemia with thrombocytopenia should be considered as TTP and the treatment must be initiated immediately like plasmapheresis, steroid, cyclophosphamide, rituximab etc. Even if rituximab is not considered as a first-choice treatment, yet it is a T
